CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus

Recruiting

Phase 1

Phase 2

CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for LupusCD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus

Sponsor:

Children's Hospital of Philadelphia

Code:

NCT06839976

Conditions

SLE

Systemic Lupus Erythematosus (SLE)

CAR T Cell

CART19

Cell Therapy

Eligibility Criteria

Sex: All

Age: 12 - 29

Healthy Volunteers: Not accepted

Interventions

CART19

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-30. This information was provided to ClinicalTrials.gov by Children's Hospital of Philadelphia on 2025-03-25.